Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 10Gastrointestinal 10Endocrine 10Sarcoma 1CNS 1

Conditions

Brain Neoplasms 151Glioblastoma 147Glioma 95Neuroblastoma 50Medulloblastoma 33Central Nervous System Neoplasms 27Astrocytoma 27Neoplasms 24Ependymoma 23Sarcoma 22Carcinoma, Non-Small-Cell Lung 22Neurofibromatosis 1 21Melanoma 20Breast Neoplasms 20Rhabdomyosarcoma 18Osteosarcoma 18Sarcoma, Ewing 16Lung Neoplasms 16Gliosarcoma 16Rhabdoid Tumor 15Oligodendroglioma 15Diffuse Intrinsic Pontine Glioma 14Wilms Tumor 13Meningioma 13Hepatoblastoma 13Recurrence 12Neurofibroma, Plexiform 11Neoplasm Metastasis 11Meningeal Carcinomatosis 11Lymphoma, Non-Hodgkin 11

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastro-enteropancreatic neuroendocrine tumor × CNS × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡